Physicians' Academy for Cardiovascular Education

AHA 2019

PACE-CME.org was present at AHA Scientific Sessions 2019 in Philadelphia, PA. Find coverage of the latest CV news on PACE-CME.

New tool can help identify FH patients

3' education - Nov. 17, 2019 - Willem Bax, Alkmaar - AHA 2019, Philadelphia

Improved health status with SGLT2-inhibitor in HFrEF

3' education - Nov. 25, 2019 - Prof. Mikhail Kosiborod - AHA 2019, Philadelphia

A rise in adverse clinical events with NOAC-regime after TAVR resulted in termination of trial

3' education - Nov. 25, 2019 - Prof. Freek Verheugt - AHA 2019, Philadelphia

Possible favorable effects of icosapent ethyl on plaque-parameters

3' education - Nov. 25, 2019 - Prof. Stephen Nicholls - AHA 2019, Philadelphia

Single dose colchicine prior to PCI reduces rise in inflammation, but does not give reduction in MI and MACE

3' education - Nov. 25, 2019 - Binita Shah - AHA 2019, Philadelphia

More evidence that aspirin may not be necessary in long-term antiplatelet therapy after ACS

3' education - Nov. 18, 2019 - Usman Baber - AHA 2019, Philadelphia

Is HF the same disease across the EF spectrum, or does HF have two physiologies that respond differently to treatment?

3' education - Nov. 18, 2019 - Prof. Lynne Stevenson - AHA 2019, Philadelphia

ARNI seems to give CV benefit not only in HFrEF, but up to EF of about 60%

3' education - Nov. 18, 2019 - Prof. Scott Solomon - AHA 2019, Philadelphia

Fish oil treatment reduces several plaque parameters after 9 months

3' education - Nov. 18, 2019 - Prof. Matthew Budoff - AHA 2019, Philadelphia

Benefit on QoL with revascularization proportional to severity of angina symptoms

3' education - Nov. 18, 2019 - Prof. John Spertus - AHA 2019, Philadelphia

Patients with moderate ischemia on a stress test do not need to go straight to the cathlab

3' education - Nov. 18, 2019 - Prof. Donald Lloyd-Jones - AHA 2019, Philadelphia

Invasive vs. conservative strategy does not reduce CV events in patients with CKD and ischemia

3' education - Nov. 17, 2019 - Sripal Bangalore, MD, New york - AHA 2019, Philadelphia

Succesful repurposing of an old anti-inflammatory drug for a new application

3' education - Nov. 16, 2019 - Aruna Pradhan, MD - AHA 2019, Philadelphia

New generation of teenagers made addicted to nicotine: it is time to act

3' education - Nov. 16, 2019 - Mariell Jessup, MD - AHA 2019, Philadelphia

Treatment with anti-inflammatory agent reduces both first and recurrent events post-MI

3' education - Nov. 16, 2019 - Jean-Claude Tardif, MD, Canada - AHA 2019, Philadelphia

PCSK9 siRNA, on top of maximally tolerated statin therapy, potently lowers LDL-c

3' education - Nov. 16, 2019 - R. Scott Wright, MD, Rochester, MN, USA - AHA 2019, Philadelphia

Consistent CV benefit and tolerability of SGLT2i in HF patients irrespective of diabetes

3' education - Nov. 16, 2019 - John McMurray, MD, Glasgow - AHA 2019, Philadelphia

New tool can help identify FH patients

3' education - Nov. 17, 2019 - Willem Bax, Alkmaar - AHA 2019, Philadelphia
A new tool, connected to the electronic patient files corrects for statin use (type and dose) to determine untreated LDL-c levels and the Dutch lipid score.

AHA 2019 A new tool, connected to the electronic patient files corrects for statin use (type and dose) to determine untreated LDL-c levels and the Dutch lipid score.

SGLT2i treatment effect not dependent on age or health status at baseline

News - Nov. 26, 2019

AHA 2019 Analyses of the DAPA-HF trial evaluated the effect of dapagliflozin across the age spectrum and based on symptoms, physical and social limitations and QoL at baseline.

Improved health status with SGLT2-inhibitor in HFrEF

3' education - Nov. 25, 2019 - Prof. Mikhail Kosiborod - AHA 2019, Philadelphia
Prof. Kosiborod describes a substudy of the DAPA-HF trial which examined whether dapagliflozin resulted in improvement of symptoms, physical limitations and QoL compared to placebo in HFrEF.

AHA 2019 Prof. Kosiborod describes a substudy of the DAPA-HF trial which examined whether dapagliflozin resulted in improvement of symptoms, physical limitations and QoL compared to placebo in HFrEF.

A rise in adverse clinical events with NOAC-regime after TAVR resulted in termination of trial

3' education - Nov. 25, 2019 - Prof. Freek Verheugt - AHA 2019, Philadelphia
The GALILEO trial compared a NOAC-based strategy with an antiplatelet-regime after TAVR to obtain insights in the best strategy. Prof. Verheugt tells us what we can learn from this trial.

AHA 2019 The GALILEO trial compared a NOAC-based strategy with an antiplatelet-regime after TAVR to obtain insights in the best strategy. Prof. Verheugt tells us what we can learn from this trial.

LDL-c target of <70 vs. 100 mg/mL after stroke lowers risk of CV events

News - Nov. 25, 2019

AHA 2019 The Treat Stroke to Target (TST) trial randomized patients with ischemic stroke or TIA with evidence of atherosclerosis to one of two LDL-c targets and found a benefit of the lower target.

Possible favorable effects of icosapent ethyl on plaque-parameters

3' education - Nov. 25, 2019 - Prof. Stephen Nicholls - AHA 2019, Philadelphia
The EVAPORATE trial was conducted to obtain insights in the mechanism of benefit with icosapent ethyl. Prof. Nicholls describes the first findings of the study.

AHA 2019 The EVAPORATE trial was conducted to obtain insights in the mechanism of benefit with icosapent ethyl. Prof. Nicholls describes the first findings of the study.

Single dose colchicine prior to PCI reduces rise in inflammation, but does not give reduction in MI and MACE

3' education - Nov. 25, 2019 - Binita Shah - AHA 2019, Philadelphia
The COLCHICINE-PCI trial investigated whether a single dose of the anti-inflammatory agent colchicine, given prior to PCI, resulted in reduced vascular inflammation and myocardial injury after PCI.

AHA 2019 The COLCHICINE-PCI trial investigated whether a single dose of the anti-inflammatory agent colchicine, given prior to PCI, resulted in reduced vascular inflammation and myocardial injury after PCI.

NOAC-based strategy after TAVR may cause harm with respect to clinical outcomes, but in contrast reduces leaflet thrombosis

News - Nov. 25, 2019

AHA 2019 A rivaroxaban-based strategy in patients after successful TAVR resulted in an increased risk of death, thromboembolic and bleeding events, but reduced markers of subclinical leaflet thrombosis compared to an antiplatelet-based regime.

APOC3 RNA silencing therapeutic safely lowers triglycerides

News - Nov. 25, 2019

AHA 2019 The siRNA ARO-APOC3 prevents production of APOC3 through RNA interference. It lowered levels of APOC3, TG and VLDL-c and increased HDL-c, and was well tolerated.

Immediate vs. delayed angiography in NSTEMI patients after cardiac arrest did not improve survival at 1 year

News - Nov. 19, 2019

AHA 2019 This analysis of the COACT trial showed that there was no difference in survival at 1 year when comparing immediate with delayed coronary angiography after cardiac arrest in NSTEMI patients.

More evidence that aspirin may not be necessary in long-term antiplatelet therapy after ACS

3' education - Nov. 18, 2019 - Usman Baber - AHA 2019, Philadelphia
TWILIGHT-ACS compared ticagrelor monotherapy with ticagrelor plus aspirin in NSTE-ACS patients who were event-free and adherent after 3 months of DAPT.

AHA 2019 TWILIGHT-ACS compared ticagrelor monotherapy with ticagrelor plus aspirin in NSTE-ACS patients who were event-free and adherent after 3 months of DAPT.

Is HF the same disease across the EF spectrum, or does HF have two physiologies that respond differently to treatment?

3' education - Nov. 18, 2019 - Prof. Lynne Stevenson - AHA 2019, Philadelphia
As a discussant of the pooled PARAGON-HF and PARADIGM-HF data, dr. Stevenson critially considers the results to get physiological clues on who should be treated and who may not benefit of ARNI.

AHA 2019 As a discussant of the pooled PARAGON-HF and PARADIGM-HF data, dr. Stevenson critially considers the results to get physiological clues on who should be treated and who may not benefit of ARNI therapy.

AHA 2019